Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 68

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 68
---
 of which are outside of our control, including, but not limited to: 

•the timing and cost of, and level of investment in, research, development, regulatory approval or certification and commercialization activities relating to our Platform and products, which may change from time to time; 

•the volume and customer mix of our Genomics and AI Applications diagnostic testing, AI Applications, and other products; 

•the start and completion of projects in which our Data and Services products are utilized; 

•the introduction of new products or product enhancements by us or others in our industry; 

•coverage and reimbursement policies with respect to our products and products that compete with our products; 

•expenditures that we may incur to acquire, develop or commercialize additional products and technologies; 

•changes in governmental regulations, including with respect to privacy and data security and medical device regulation, and our compliance therewith, or in the status of our regulatory approvals, certifications or applications; 

•future accounting pronouncements or changes in our accounting policies; 

•developments or disruptions in the business and operations of our clinical, commercial and other partners; 

•the impact of natural disasters, political and economic instability, including wars (such as the armed conflicts between Russia and Ukraine and the hostilities in the Middle East), terrorism, and political unrest, epidemics or pandemics, boycotts, curtailment of trade and other business restrictions; and 

•general market conditions, including high and rising inflation rates, high interest rates, government bank closures, liquidity concerns at other financial institutions, and other factors, including factors unrelated to our operating performance or the operating performance of our competitors. 

Additionally, it is difficult to predict the amounts, if any, we will be able to collect for our diagnostic tests from commercial payers. We are a participating network provider in a small number of commercial payers from whom we receive reimbursement for our diagnostic tests. Payers determine the amount they are willing to reimburse us for tests. We have provided testing to patients with many disease types and indications, most of the time as a non-participating provider. Even when payers have paid a claim, they may elect at any time to review previously paid claims for overpayment against these claims. While we have not experienced significant retroactive adjustments to date, in the event of an overpayment determination, the payer may offset the amount they determine they overpaid against amounts they owe us on current claims. 

54

We have limited leverage to dispute these retroactive adjustments and we cannot predict